Laboratory & Allied (Lab & Allied), the largest indigenous pharmaceutical manufacturing company in Kenya, is seeking to expand its operations in East Africa in the next five years as part of its expansion strategy.
The company has invested over Ksh2.2 billion to enhance its production capacity and increase its operations to serve the new markets as it marks its 45 years anniversary. Making the announcement, Lab & Allied Chief Executive Officer Suprakash Mandal said the company is seeking new investments opportunities to spur growth in the region.
Lab & Allied CEO Suprakash Mandal and Business Development Manager Nitya Patel during the launch of five years expansion strategy.
“It is our hope that this investment will enable us to provide better medicine and in essence, a better life for the consumers that we serve. We are looking at investing Ksh2.2 billion towards expanding our operations in Ethiopia, Angola and Democratic Republic of Congo (DRC) to enable us tap into the growing 150 million population in the region,” said Mr Mandal.
The company, which deals in the production of human and veterinary products, announced its entry into the therapeutic medicine segment that will address the emerging lifestyle diseases as well address the new disease patterns in the country and the region.
“We are also looking into introducing high-end antibiotics to support clients whom are developing some level of resistant. We are moving into the segment of drugs required by medical specialists and consultants which so far has been dominated by products which are imported,” added Mr Mandal.
NEXT READ: HUMAN RESOURCE PROFESSIONALS TO BE VETTED
Leave a comment